Eli Lilly Has Been on an Acquisition Spree. How Much Could Its Latest Deals Boost the Stock?
Key PointsEli Lilly's most important drugs right now are Mounjaro, Zepbound, and, to a lesser degree, Foundayo.
Eli Lilly is engaged in an acquisition frenzy, and the impact of its latest deals on the stock price remains uncertain. However, these acquisitions could serve as the groundwork for the pharmaceutical giant's future growth. To understand the company's current situation, it is essential to examine its second-quarter revenues. Mounjaro, Zepbound, and Foundayo are responsible for nearly two-thirds of Eli Lilly's top line.
These drugs target the same health issue: weight loss. Despite being a drug maker, Eli Lilly's success lies in its weight-loss drugs, which have become crucial products for the company.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
